Company Active LTD

Company profile

Diagnodus Ltd

DiagNodus: Colorectal Diagnostic Technologies

A biotechnology company developing novel diagnostic tools in the area of colorectal disease

CRN
07600875
Founded
2011
Age
15

Overview

Legal name
DIAGNODUS LTD
Region
East of England
Registered address
ST JOHN'S INNOVATION CENTRE
COWLEY ROAD
CAMBRIDGE
ENGLAND
CB4 0WS
Insolvency history
No

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Jan
2027

Accounts due

Accounts Due

Next accounts due date

26 Apr
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

30 Apr
2025

Accounts filed

Accounts

Last accounts made up date

12 Apr
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

12 Apr
2011

Incorporated

Inception

Company registered at Companies House

Public funding

3 awards
First funded
2013
Funded years
2013, 2017, 2020
Age at first award
2 years

Projects

2020 Feasibility Studies Lead participant

Detection of SARS-CoV-2 RNA presence in colorectal mucus collected from patients recovering from COVID-19 for assessing the risk of exposure to the virus in medical professionals performing invasive colorectal procedures including endoscopy.

1 Jul 2020 to 31 Mar 2021

Awarded
£75,000
Total cost £75,000

The COVID-19 pandemic not only affects millions of people, but also generates high levels of risk for medical professionals caring for their patients. It is established that the virus induces predominantly respiratory symptoms that are often culminated by the development of severe pneumonias, and COVID-19 mostly spreads through aerosol droplets generated ...

2017 Feasibility Studies Lead participant

Colorectal cancer detection by quantifying biomarkers in non-invasively collected colorectal mucus.

1 Feb 2017 to 31 Jan 2018

Awarded
£140,000
Total cost £200,000

Colorectal cancer (CRC) is a severe disease causing about 10% of all cancer deaths in the UK. Many CRC cases are diagnosed too late to be successfully treated, and early detection of CRC remains an urgent healthcare problem. This project aims to evaluate the feasibility of our recently invented technique of non-invasive sample collection and analysis as a...

2013 GRD Proof of Concept Lead participant

Development of new non-invasive tests for inflammatory bowel disease detection, monitoring and treatment assessment.

1 Sep 2013 to 28 Feb 2015

Awarded
£100,000
Total cost £171,823

Inflammatory bowel disease (IBD) is a group of common chronic diseases involving bowel inflammation. Ulcerative colitis and Crohn’s disease are the most important conditions of this group. IBD is usually diagnosed in young adults. As a rule it is characterized by long remissions and incidental flare-ups requiring treatment. IBD should be distinguished fro...

Product types

Feasibility Studies GRD Proof of Concept